Barinthus Biotherapeutics (BRNS) Profit After Tax (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has 7 years of Profit After Tax data on file, last reported at -$8.4 million in Q1 2026.

• Quarterly Profit After Tax rose 44.25% year-over-year to -$8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.9 million (up 6.17% YoY) and the FY2025 annual result came in at -$56.3 million, up 11.53% from the prior year.
• Profit After Tax improved to -$8.4 million in Q1 2026, from -$10.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $15.7 million in Q2 2022 to a low of -$30.9 million in Q4 2024.
• A 5-year average of -$12.1 million and a median of -$15.5 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax jumped 280.4% — and 2025, when it tumbled 1739.83%.
• Tracing BRNS's Profit After Tax over 5 years: stood at -$21.2 million in 2022, then increased by 7.72% to -$19.6 million in 2023, then tumbled by 57.8% to -$30.9 million in 2024, then soared by 64.54% to -$10.9 million in 2025, then rose by 23.56% to -$8.4 million in 2026.
• The last three Profit After Tax figures came in at -$8.4 million (Q1 2026), -$10.9 million (Q4 2025), and -$17.5 million (Q3 2025), per Business Quant data.